Meyahealth
HomeGeneticsGeneGNA11 gene
Back to Gene
GNA11 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GNA11 gene

The GNA11 gene provides instructions for creating a protein subunit essential for signal transduction, a process that influences cell growth, hormone regulation, and calcium levels.

Normal Function

The GNA11 gene provides instructions for making the alpha (α) subunit of a protein complex called a guanine nucleotide-binding protein (G protein), specifically the G11 protein. G proteins are composed of three subunits: alpha, beta, and gamma.

Through a process called signal transduction, G proteins trigger signaling pathways that influence various cell functions. The G11 protein works with the calcium-sensing receptor (CaSR) to regulate blood calcium levels. In the kidneys and parathyroid gland, the CaSR protein stimulates Gα11 to block processes that increase blood calcium, such as the release of parathyroid hormone. Additionally, G11 signaling is involved in the growth, division (proliferation), and self-destruction (apoptosis) of cells in tissues including the skin, eyes, heart, and brain.

Health Conditions Related to Genetic Changes

Autosomal dominant hypocalcemia

Mutations in the GNA11 gene can lead to autosomal dominant hypocalcemia type 2, characterized by low blood calcium levels (hypocalcemia). These activating mutations cause the Gα11 subunit to become overactive, blocking the rise of calcium levels even when they are already low. This can lead to:

  • Muscle cramping
  • Seizures
  • Hypoparathyroidism (abnormally low levels of parathyroid hormone)

Other disorders

Genetic changes that impair Gα11 signaling cause familial hypocalciuric hypercalcemia type 2. This condition is characterized by high levels of calcium in the blood (hypercalcemia) and low levels of calcium in the urine (hypocalciuria). Affected individuals typically do not exhibit symptoms.

Cancers

Somatic mutations in the GNA11 gene—changes acquired during a person's lifetime rather than inherited—are associated with certain tumors:

  • Uveal melanomas: Cancerous tumors occurring in the iris, ciliary body, or choroid of the eye.
  • Blue nevus: A typically noncancerous skin tumor characterized by a bluish appearance.

These mutations lead to an overactive Gα11 protein, stimulating the uncontrolled proliferation of pigment-producing cells (melanocytes).

Frequently Asked Questions

Patients with GNA11-related hypocalcemia should be vigilant for signs of severe hypocalcemia, which can become life-threatening. Emergency triggers include muscle spasms or cramping (tetany), tingling around the mouth or in the fingers and toes, and in severe cases, seizures or cardiac arrhythmias. If a patient experiences these symptoms, they should seek immediate medical attention. Regular monitoring of serum calcium levels is essential to prevent these acute episodes, as the body's natural feedback loop is impaired by the overactive G protein.
Familial hypocalciuric hypercalcemia type 2 (FHH2) is caused by loss-of-function mutations in GNA11 and is typically asymptomatic, meaning most people do not experience symptoms despite high blood calcium levels. Unlike primary hyperparathyroidism, which often requires parathyroid surgery, FHH2 is generally managed with observation and monitoring rather than invasive treatment. The key distinction is that FHH2 involves low calcium excretion in the urine, whereas primary hyperparathyroidism usually presents with normal or high urinary calcium and often causes kidney stones or bone loss.
Somatic GNA11 mutations are acquired changes that occur in specific tissues, such as the skin or colon, and are not present in every cell of the body. Therefore, they are not detected by standard blood-based genetic screening or routine cancer screenings like mammograms or colonoscopies. These mutations are typically identified through molecular testing of tumor tissue during or after a cancer diagnosis. They are associated with certain cancers, including melanoma and colorectal cancer, but their presence is a feature of the tumor's biology rather than a hereditary risk factor that can be screened for in healthy individuals.
Yes, GNA11 signaling is involved in calcium homeostasis in the kidneys as well as the parathyroid glands. In the kidneys, the calcium-sensing receptor works with GNA11 to regulate how much calcium is reabsorbed into the blood versus excreted in urine. Mutations that impair this signaling can lead to the characteristic low urinary calcium seen in FHH2. Additionally, GNA11 plays a role in cell growth and apoptosis in tissues like the skin, eyes, and brain, suggesting that genetic changes may have broader physiological impacts beyond just calcium levels.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ